Fig. 2From: EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapyImmunological activation profile of EnanDIM-C (a-c), EnanDIM-A (d-f) and differences between both molecules (g, h). Human PBMC were treated without (black open squares) or with EnanDIM molecules (blue filled squares) at a final concentration of 3āĪ¼M for 48āh. Cytokines/chemokines were measured in cell culture supernatants (a nĀ =ā14ā48, d nĀ =ā12ā38, h nĀ =ā21) and activation of immune cells was analyzed by flow cytometry (b nĀ =ā13ā29, c, e nā=ā12ā34, f, g). Means are shown, differences between EnanDIMĀ®-treated PBMC and controls were calculated using the paired t-test (*pĀ <ā0.05, **pĀ <ā0.01 ***pĀ <ā0.001) (a, b, d, e, h). Results from representative experiments are shown (c MFI of CD169 within monocytes is shown, f frequency of CD86 within B cells is shown, g HLA-DR expression of pDC)Back to article page